PRISM BioLab206A東証グロース医薬品FY ending Sep 2025, non-consolidated, J-GAAP

PRISM BioLab FY ending Sep 2023 results

PRISM BioLab brought in ¥112.9M in revenue.

It lost about ¥440 for every ¥100 of sales at the operating level.

Where the money goes

Where ¥100 of sales goes

For every ¥100 PRISM BioLab sells, how much goes where, and how much is kept.

FY ending Sep 2023
Cost of sales
¥29
SG&A
¥511
Operating loss
¥440
Net loss
¥467

Margin funnel (derived from reported values)Gross margin 71.1% → Operating margin -440.0% → Net margin -466.6%

Sources

Show source documents (2)
  • EDINET (FSA Japan)

    有価証券報告書-第14期(2024/10/01-2025/09/30)

    ID S100XCIN2025-12-24Open
  • EDINET (FSA Japan)

    有価証券報告書-第13期(2023/10/01-2024/09/30)

    ID S100V11F2024-12-27Open

Extracted from XBRL: 31 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.